Lastacaft

(Alcaftadine)

ApprovedSmall molecule

AbbVie

Lastacaft is one of 22 small molecule programs targeting Allergy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

AllergyUnknown status

AllergyApproved

Unknown status

Competition

Competitive Landscape

30 competitors in Allergy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Flagyl

DDePuy Orthopaedics

Approved

1 4

Claritin

PPerrigo Company

Approved

1 5

Potassium Citrate

MMission Pharmacal

Approved

1 6

Levaquin

WWim Janssens

Approved

1 7

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 8

Allegra

CChattem

Approved

1 9

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 10

Lastacaft

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergy1 trial

Ocular Allergy Treatment Practical Impact Trial

Unknown status·SStarx Research Center, LLC·Phase 4·NCT01808768·50 enrolled

Eye Allergy1 trial

Safety and Efficacy Study of a Eye Drop for Eye Allergy

Completed·VVistakon Pharmaceuticals·Phase 3·NCT00889330·60 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 28, 2010

LASTACAFT

NDA NDA022134

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Alcaftadine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alcaftadine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alcaftadine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022134). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Lastacaft. U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Patent Landscape[5]

Patent Cliff

Mar 19, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10617695Mar 19, 2027

8664215Dec 23, 2027

Lastacaft

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergy1 trial

Eye Allergy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News